

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

CLOSURE OF THE REGISTER OF MEMBERS

Reference is made to the announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 27 October 2023 in relation to the proposed amendments to the Company’s articles of association and the announcement of the Company dated 9 November 2023 (the “**Announcement**”) in relation to, among others, entering into the 2023 Procurement Framework Agreement and the 2023 Sales Framework Agreement between the Company and CNPGC and the 2023 Financial Services Framework Agreement between the Company and the Finance Company. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company proposed to convene and hold an extraordinary general meeting on Wednesday, 20 December 2023 to seek the approval of the Shareholders with respect to the proposed amendments to the Company’s articles of association, the terms of, the continuing connected transactions contemplated under and the proposed annual caps for the 2023 Procurement Framework Agreement and the 2023 Sales Framework Agreement, and the terms of, the Deposit Services contemplated under and the proposed maximum daily balances of the Deposit Services under the 2023 Financial Services Framework Agreement. A circular containing, among others, details of the proposed amendments to the Company’s articles of association, details of the continuing connected transactions contemplated under and the proposed annual caps for the 2023 Procurement Framework Agreement and the 2023 Sales Framework Agreement and details of the Deposit Services contemplated under and the proposed maximum daily balances of the Deposit Services under the 2023 Financial Services Framework Agreement, together with a notice of the extraordinary general meeting, is expected to be despatched to the Shareholders on or before 5 December 2023.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

For the purpose of holding the extraordinary general meeting, the register of members of the Company (the “**Register**”) will be closed from Friday, 15 December 2023 to Wednesday, 20 December 2023 (both days inclusive), during which no transfer of shares of the Company will be registered.

In order to be qualified to attend and vote at the extraordinary general meeting, for holders of H shares of the Company, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited (address: Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong) as soon as practicable, and in any event no later than 4:30 p.m. on Thursday, 14 December 2023.

Shareholders whose names appear on the Register on Friday, 15 December 2023 are entitled to attend and vote at the extraordinary general meeting.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
1 December 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dong Jiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.